Oramed Pharmaceuticals Inc. (NASDAQ:ORMP)
| Market Cap | 178.85M+82.8% |
| Revenue (ttm) | 0-100.0% |
| Net Income | 174.87M+823.7% |
| EPS | 4.11+762.9% |
| Shares Out | 40.93M |
| PE Ratio | 1.03 |
| Forward PE | n/a |
| Dividend | $0.25(5.72%) |
| Ex-Dividend Date | Jan 16, 2026 |
| Volume | 84,726 |
| Open | 4.42 |
| Previous Close | 4.38 |
| Day's Range | 4.35 - 4.45 |
| 52-Week Range | 2.09 - 5.47 |
| Beta | 1.28 |
| Analysts | Buy |
| Price Target | n/a |
| Earnings Date | Nov 12, 2026 |
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
About ORMP
Oramed Pharmaceuticals Inc., founded in 2002 and based in New York, New York, specializes in the development of groundbreaking pharmaceutical treatments. Their primary focus is on creating orally ingested capsules or pills for the delivery of polypeptides, particularly aimed at managing diabetes. The company's leading product, ORMD-0801, is an oral insulin capsule that has successfully completed Phase II clinical trials for patients with diabetes. Oramed is also advancing ORMD-0901, an oral glucagon-like peptide-1 (GLP-1) capsule, which has concluded Phase I clinical trials for the treatment of type 2 diabetes. Additionally, an oral leptin capsule for weight loss is currently under development. The firm was originally incorporated as Integrated Security Technologies, Inc., before officially changing its name to Oramed Pharmaceuticals Inc. in April 2006.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$ORMP stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in ORMP holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by ORMP's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
ORMP Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New ORMP patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to ORMP from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in ORMP
| ETF | Est. Holding Size |
|---|---|
| IWMiShares Russell 2000 ETF | $3.73M |
| VTWOVanguard Russell 2000 ETF | $986.17K |
| IWCiShares Micro-Cap ETF | $477.32K |
| SILXETFMG Prime 2x Daily Junior Silver Miners ETF | $325.28K |
| VALTETFMG Sit Ultra Short ETF | $319.37K |
| DFASDimensional - US Small Cap ETF | $267.68K |
Estimated from each fund’s disclosed top holdings × AUM
ORMP Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from ORMP’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score